TEAD palmitoylation inhibitors like those developed by Vivace Therapeutics were first tested in NF2-deficient mesothelioma and have also been effective in reducing Schwannoma tumor size in vivo without side effects [13,14]. Here, NF2 is linked to neoplasm.